Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of RVMD is 92 and suggests 22% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Buy
Sell